NEW YORK, March 31, 2025 /PRNewswire/ --Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that it has received an official Filing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback